Literature DB >> 1357162

Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger.

T L Yue1, H Y Cheng, P G Lysko, P J McKenna, R Feuerstein, J L Gu, K A Lysko, L L Davis, G Feuerstein.   

Abstract

The antioxidant effect of carvedilol, a new vasodilating, beta adrenoceptor blocker was studied and compared with five other beta blockers. Carvedilol rapidly inhibited Fe(++)-initiated lipid peroxidation, measured as thiobarbituric acid reactive substance (TBARS), in rat brain homogenate with an IC50 of 8.1 microM. Under the same conditions, the IC50 values of atenolol, pindolol propranolol, celiprolol and labetalol were over 1.0 mM. Carvedilol protected against Fe(++)-induced alpha-tocopherol depletion in rat brain homogenate with an IC50 of 17.6 microM; propranolol, celiprolol and labetalol, up to 200 microM, did not show any effect. Using dihydroxyfumarate/Fe(++)-ADP as a OH.radical generating system and 5,5-dimethyl pyrroline-N-oxide (DMPO) as a trapping agent, the characteristic DMPO-OH signals were monitored by electron paramagnetic resonance. Carvedilol dose-dependently decreased the intensity of the DMPO-OH signal, with an IC50 of 25 microM, whereas propranolol, at 500 microM, and U74500A, a 21-aminosteroid, at 100 microM, had no effect. The antioxidant effect of carvedilol mainly resides in the carbazole moiety, and the substitution of a hydroxyl group at certain positions on the phenyl ring of either carbazole or the ortho-substituted phenoxylethylamine part of carvedilol resulted in an increase in antioxidant activity. Furthermore, the protective effect of carvedilol analogs against OH.-mediated neuronal death positively correlated to their antioxidant effect. We conclude that carvedilol is a far more potent antioxidant than other commonly used beta blockers. The apparent mechanism of carvedilol's inhibition of lipid peroxidation is mainly via scavenging free radicals. This novel property of carvedilol may contribute to the known cardioprotective activity of this compound.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357162

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  75 in total

1.  Prevention of skin carcinogenesis by the β-blocker carvedilol.

Authors:  Andy Chang; Steven Yeung; Arvind Thakkar; Kevin M Huang; Mandy M Liu; Rhye-Samuel Kanassatega; Cyrus Parsa; Robert Orlando; Edwin K Jackson; Bradley T Andresen; Ying Huang
Journal:  Cancer Prev Res (Phila)       Date:  2014-11-03

Review 2.  Heart failure in African Americans: unique etiology and pharmacologic treatment responses.

Authors:  Clyde W Yancy
Journal:  J Natl Med Assoc       Date:  2003-01       Impact factor: 1.798

3.  The effect of losartan and carvedilol on renal haemodynamics and altered metabolism in fructose-fed Sprague-Dawley rats.

Authors:  Mohammed H Abdulla; Munavvar A Sattar; Nor A Abdullah; Edward J Johns
Journal:  J Physiol Biochem       Date:  2012-01-27       Impact factor: 4.158

Review 4.  Initiation and use of beta-blockers in class IV heart failure.

Authors:  Feras M Bader; John F MacGregor; Edward M Gilbert
Journal:  Curr Heart Fail Rep       Date:  2004-07

5.  Novel carvedilol analogues that suppress store-overload-induced Ca2+ release.

Authors:  Chris D Smith; Aixia Wang; Kannan Vembaiyan; Jingqun Zhang; Cuihong Xie; Qiang Zhou; Guogen Wu; S R Wayne Chen; Thomas G Back
Journal:  J Med Chem       Date:  2013-11-05       Impact factor: 7.446

6.  Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol.

Authors:  Sakir Arslan; Mustafa Kemal Erol; Engin Bozkurt; Mahmut Acikel; Fuat Gundogdu; Sebahattin Atesal; Huseyin Senocak
Journal:  Int J Cardiovasc Imaging       Date:  2006-12-14       Impact factor: 2.357

Review 7.  Choosing the right beta-blocker. A guide to selection.

Authors:  J R Hampton
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

Review 8.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

9.  Metabolic effects of carvedilol through β-arrestin proteins: investigations in a streptozotocin-induced diabetes rat model and in C2C12 myoblasts.

Authors:  Berna Güven; Zümra Kara; Arzu Onay-Beşikci
Journal:  Br J Pharmacol       Date:  2020-11-15       Impact factor: 8.739

10.  Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury.

Authors:  E H Ohlstein; S A Douglas; C P Sung; T L Yue; C Louden; A Arleth; G Poste; R R Ruffolo; G Z Feuerstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.